Investigational Drug Information for SAR439859
✉ Email this page to a colleague
What is the development status for investigational drug SAR439859?
SAR439859 is an investigational drug.
There have been 9 clinical trials for SAR439859.
The most recent clinical trial was a Phase 1 trial, which was initiated on October 14th 2020.
The most common disease conditions in clinical trials are Breast Neoplasms, Triple Negative Breast Neoplasms, and Hemangiosarcoma. The leading clinical trial sponsors are Sanofi, Stanford University, and Alliance for Clinical Trials in Oncology.
Summary for SAR439859
| US Patents | 0 |
| International Patents | 32 |
| US Patent Applications | 23 |
| WIPO Patent Applications | 14 |
| Japanese Patent Applications | 3 |
| Clinical Trial Progress | Phase 1 (2020-10-14) |
| Vendors | 30 |
Recent Clinical Trials for SAR439859
| Title | Sponsor | Phase |
|---|---|---|
| Umbrella Trial Testing Integrative Subtype-Targeted Therapeutics in HR+ /HER2-Negative Breast Cancer | United States Department of Defense | Phase 2 |
| Umbrella Trial Testing Integrative Subtype-Targeted Therapeutics in HR+ /HER2-Negative Breast Cancer | Stanford University | Phase 2 |
| Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity | Alliance for Clinical Trials in Oncology | Phase 3 |
Clinical Trial Summary for SAR439859
Top disease conditions for SAR439859
Top clinical trial sponsors for SAR439859
US Patents for SAR439859
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for SAR439859
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| SAR439859 | Argentina | AR107616 | 2036-02-15 | ⤷ Sign Up |
| SAR439859 | Australia | AU2017221083 | 2036-02-15 | ⤷ Sign Up |
| SAR439859 | Brazil | BR112018016490 | 2036-02-15 | ⤷ Sign Up |
| SAR439859 | Canada | CA3014424 | 2036-02-15 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
